NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial

Zev A Wainberg, MD – Davide Melisi, MD – Teresa Macarulla, MD – Roberto Pazo Cid, MD – Sreenivasa R Chandana, MD – Christelle De La Fouchardière, MD – Andrew Dean, MD – Igor Kiss, MD – Woo Jin Lee, MD – Thorsten O Goetze, MD – Eric Van Cutsem, MD – A Scott Paulson, MD – Tanios Bekaii-Saab, MD – Shubham Pant, MD – Richard A Hubner, MD –
Zhimin Xiao, MD – Huanyu Chen, PhD – Fawzi Benzaghou, MD – Eileen M O’Reilly, MD

The Lancet Journal, October 07, 2023

Abstract link